An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

恢复卵巢癌卡铂敏感性的表观遗传学策略

基本信息

项目摘要

Project Summary/Abstract Platinum resistance in ovarian cancer is associated with accumulation of epigenetic changes leading to transcriptional silencing of tumor suppressor and chemo-responsiveness-associated genes. A clinical trial designed and conducted previously demonstrated that methylome-targeted interventions reverse platinum resistance and induce clinical responses. Building upon this work, we propose to extend the ovarian cancer epigenome analysis by using MBDCap-sequencing and bioinformatics and to test the effects of SGI-110, a novel DNA methyl transferase inhibitor (DNMTI). The hypothesis to be tested is that platinum resistance in ovarian cancer is uniquely reflected in DNA methylation changes and can be reversed by DNMTI. To address this hypothesis, tumor and plasma samples collected from an ongoing randomized phase II clinical trial comparing SGI-110 and carboplatin to FDA-approved strategies for platinum-resistant ovarian cancer will be analyzed. Clinical specimens from ~100 patients will be available for analysis. Three aims are proposed. For Aim 1, DNMTI-induced changes in the ovarian cancer methylome will be measured by using MethylCap-seq on tumor biopsies obtained before and after SGI-110. The objective of this Aim is to investigate whether SGI-110 induces global methylome changes affecting networks of genes associated with chemo-responsiveness. The objective of Aim 2 is to determine whether DNMT expression levels differ in recurrent vs. primary tumors and whether expression levels at enrollment or changes induced by DNMTIs correlate with clinical benefit. For Aim 3, the objective is to determine whether specific genes methylation levels at enrollment and changes induced by DNMTIs correlate with clinical benefit. This project will identify critical DNA methylation events that govern the development of platinum resistance. The proposed studies are highly innovative based on the use of state-of- the-art MBDCap-Seq and bioinformatics applied to a question of high clinical relevance. Successful completion of the correlative work integrated in this trial will identify predictive markers of response to methylome-targeting strategies. This study will bring epigenetic interventions to the forefront of therapy for ovarian cancer impacting treatment strategies and outcomes for this deadly cancer. Successful completion of this study will move forward the field of epigenome-targeted therapy for solid tumors and will provide key information for biologically- directed future design of phase III trials.
项目总结/摘要 卵巢癌中的铂耐药与表观遗传变化的积累相关, 肿瘤抑制和化学反应相关基因的转录沉默。临床试验 先前设计和进行的研究表明,甲基化靶向干预逆转了铂 耐药性并诱导临床反应。在这项工作的基础上,我们建议将卵巢癌 使用MBDCap-测序和生物信息学进行表观基因组分析,并测试SGI-110的作用 新的DNA甲基转移酶抑制剂(DNMTI)。待检验的假设是, 卵巢癌是唯一反映在DNA甲基化的变化,可以逆转DNMTI。到 为了解决这一假设,从正在进行的随机II期临床试验中收集的肿瘤和血浆样本 将SGI-110和卡铂与FDA批准的铂类耐药卵巢癌治疗策略进行比较, 分析了约100例患者的临床标本可用于分析。提出了三个目标。为 目的1,将通过使用MethylCap-seq检测DNMTI诱导的卵巢癌甲基化组的变化。 在SGI-110之前和之后获得的肿瘤活组织检查。本目标的目的是调查SGI-110是否 诱导影响与化学反应性相关的基因网络的整体甲基化组变化。的 目的2的目的是确定复发性肿瘤与原发性肿瘤中DNMT表达水平是否不同, 是否在登记时的表达水平或由DNMTIs诱导的变化与临床益处相关。为宗旨 3、目的是确定是否有特定基因在入组时甲基化水平的变化所诱导 DNMTI与临床获益相关。该项目将确定关键的DNA甲基化事件, 铂电阻的发展。拟议的研究是高度创新的基础上使用的国家- 最新的MBDCap-Seq和生物信息学应用于高度临床相关性的问题。成功完成 本试验中整合的相关工作将确定对甲基化靶向反应的预测标志物 战略布局这项研究将把表观遗传干预带到卵巢癌治疗的最前沿, 治疗策略和结果。成功完成这项研究将推动 推进了实体瘤表观基因组靶向治疗领域,并将为生物学- 指导未来III期试验的设计。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniela E Matei其他文献

Daniela E Matei的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniela E Matei', 18)}}的其他基金

Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer
了解铂类耐药卵巢癌的代谢重编程
  • 批准号:
    10485428
  • 财政年份:
    2022
  • 资助金额:
    $ 32.37万
  • 项目类别:
Research Test-Bed Unit
研究试验台装置
  • 批准号:
    10539329
  • 财政年份:
    2021
  • 资助金额:
    $ 32.37万
  • 项目类别:
Research Test-Bed Unit
研究试验台装置
  • 批准号:
    10375271
  • 财政年份:
    2021
  • 资助金额:
    $ 32.37万
  • 项目类别:
Center for Chromatin NanoImaging in Cancer
癌症染色质纳米成像中心
  • 批准号:
    10830067
  • 财政年份:
    2021
  • 资助金额:
    $ 32.37万
  • 项目类别:
Project 02: Tumor Methylomics Analysis Link with Racial Disparities in Ovarian Cancer
项目02:肿瘤甲基组学分析与卵巢癌种族差异的联系
  • 批准号:
    10488640
  • 财政年份:
    2020
  • 资助金额:
    $ 32.37万
  • 项目类别:
Project 02: Tumor Methylomics Analysis Link with Racial Disparities in Ovarian Cancer
项目02:肿瘤甲基组学分析与卵巢癌种族差异的联系
  • 批准号:
    10265428
  • 财政年份:
    2020
  • 资助金额:
    $ 32.37万
  • 项目类别:
An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer
恢复卵巢癌卡铂敏感性的表观遗传学策略
  • 批准号:
    8806535
  • 财政年份:
    2014
  • 资助金额:
    $ 32.37万
  • 项目类别:
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer
组织动力学成像对卵巢癌治疗效果的影响
  • 批准号:
    9085110
  • 财政年份:
    2013
  • 资助金额:
    $ 32.37万
  • 项目类别:
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer
组织动力学成像对卵巢癌治疗效果的影响
  • 批准号:
    8471381
  • 财政年份:
    2013
  • 资助金额:
    $ 32.37万
  • 项目类别:
Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer
组织动力学成像对卵巢癌治疗效果的影响
  • 批准号:
    8656327
  • 财政年份:
    2013
  • 资助金额:
    $ 32.37万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 32.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了